CIDP Cohort: Chronically inflammatory demyelinating polyneuropathy: diagnostic, prognostic and therapy response markers
The course and degree of severity of chronic-inflammatory demyelinating polyneuropathy (CIDP) vary greatly among individual cases. Especially in younger patients (approx. 30% of cases), relapse remitting courses can be observed. To date there have been no clinical, genetic or immunological markers that permit prediction of the course of the disease and thus a prognosis of the CIDP. By means of the CIDP Cohort it is intended to identify prognosis parameters can predict the course of the disease, but also the therapeutic response to therapy and the long-term outcome early on. In addition, biomarkers are to be identified that predict the disease activity (remissions and/or exacerbation of the disease). Furthermore, new scientific hypotheses and findings are to be investigated on the basis of the study population, which is to have been systematically examined for a period of ten years and is expected to be very well characterized.
Principle Investigator: Dr. Juliane Klehmet (WG Cerebrovascular Diseases, NCRC, Neurology CCM)
Course of the study: 2021
Klehmet, J., S. Beutner, S. Hoffmann, M. Dornauer, F. Paul, R. Reilmann, A. U. Brandt, and A. Meisel. "Quantitative Grip Force Assessment of Muscular Weakness in Chronic Inflammatory Demyelinating Polyneuropathy." BMC Neurol 19, no. 1 (Jun 8 2019): 118. https://dx.doi.org/10.1186/s12883-019-1339-x.
Stascheit, F., B. Hotter, S. Klose, C. Meisel, A. Meisel, and J. Klehmet. "Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-a Potential Novel Biomarker of Disease Activity." Front Neurol 12 (2021): 723009. https://dx.doi.org/10.3389/fneur.2021.723009.